Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin (Cor16)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01613729 |
Recruitment Status : Unknown
Verified September 2012 by D16 Pharma & Biotec Ltd..
Recruitment status was: Enrolling by invitation
First Posted : June 7, 2012
Last Update Posted : September 25, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dyslipidemia | Drug: Rosuvastatin 5 mg Drug: Rosuvastatin 10 mg | Phase 4 |
This study will observe the followings:
- To compare the effect of 5 mg/10 mg Rosuvastatin by assessment of the number of patients reaching LDL-C target goal after 24 weeks of therapy.
- To compare the effect of 12 weeks therapy with 5 mg/10 mg Rosuvastatin on change in LDL-C (compare change from baseline).
- To investigate the effect of 12 weeks therapy with 10 mg Rosuvastatin on change in LDL-C (compare values week 0 vs. week 12).
- To investigate the safety of Rosuvastatin in regards to liver enzyme change, kidney function and muscle toxicity.
- To compare the effect of 12 weeks therapy with 5 mg/10 mg Rosuvastatin on change in TC, HDL-C, TG, LDL-C density and HbA1c (compare change from baseline).
- To investigate the effect of 12 weeks therapy with 10 mg Rosuvastatin on change in TC, HDL-C, TG, LDL-C density and HbA1c (compare values week 0 vs. week 12).
- To investigate the effect of 12 weeks therapy on change in microalbuminuria in each treatment group (compare change from baseline).
-
To investigate the effect of 12 weeks therapy on change in BMI (compare change from baseline).
The effects of the dose increase and the dose decrease from weeks 12 to 24 will be evaluated as follows:
- To investigate the change in LDL-C by increasing the dose from 5 mg to 10 mg (compare values week 12 vs. 24).
- To investigate the change in LDL-C by decreasing the dose from 10 mg to 5 mg (compare values week 12 vs. 24).
- To investigate the change in TC, HDL-C, TG, LDL-C density and HbA1c by increasing the dose from 5 mg to 10 mg (compare values week 12 vs. 24).
- To investigate the change in TC, HDL-C, TG, LDL-C density and HbA1c by decreasing the dose from 10 mg to 5 mg (compare values week 12 vs. 24).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2000 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin |
Study Start Date : | July 2012 |
Estimated Primary Completion Date : | July 2013 |
Estimated Study Completion Date : | December 2013 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Rosuvastation 5 Initiator Arm
These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
|
Drug: Rosuvastatin 5 mg
Rosuvastatin 5 mg |
Active Comparator: Rosuvastatin 10 initiator arm
These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
|
Drug: Rosuvastatin 10 mg |
- Efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy. [ Time Frame: 24 weeks ]
- To compare the safety [ Time Frame: 24 weeks ]
To investigate the effect of 12 weeks therapy on change in microalbuminuria in each treatment group (compare change from baseline).
To investigate the effect of 12 weeks therapy on change in BMI (compare change from baseline).
The effects of the dose increase and the dose decrease from weeks 12 to 24 will be evaluated
to investigate the safety of Rosuvastatin in regards to Liver enzyme change, kidney function and muscle toxicity.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 45 - 75 years
- LDL - C between 130 mg/dL and 250 mg/dL
- TG < 400 mg/dL
- HbA1c < 7%
- Written informed consent to participate in the trial
Exclusion Criteria:
- Known hypersensitivity or history of SAE with another HMG-CoA reductase inhibitor, in particular any history of myopathy
- Active liver disease/severe hepatic impairment
- Treatment with cyclosporin or any disallowed drug
- Patients with unstable angina pectoris

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01613729
Bangladesh | |
BSMMU | |
Dhaka, Bangladesh, 1000 |
Principal Investigator: | Nazrul Islam, FCPS | Professor of Cardiology | |
Study Director: | Pinaki Bhattacharya, MBBS | D16 Pharma & Biotec |
Responsible Party: | D16 Pharma & Biotec Ltd. |
ClinicalTrials.gov Identifier: | NCT01613729 |
Other Study ID Numbers: |
corestin/bd/2012-16 |
First Posted: | June 7, 2012 Key Record Dates |
Last Update Posted: | September 25, 2012 |
Last Verified: | September 2012 |
Dyslipidemia Rosuvastatin Efficacy Safety |
Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Rosuvastatin Calcium Anticholesteremic Agents Hypolipidemic Agents |
Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |